DNA DAMAGE RESPONSE TARGETING THERAPEUTICS (BEYOND PARP INHIBITORS)

During our research, we came across over 43 companies that are presently engaged in the development of DDR targeting therapeutics. There has been a significant increase in the number of developers that have been established in this domain post-2008. In fact, close to XX players were established during the period 2013-2016. Further, over XX developers have been founded since 2017.

To order this 130+ slides report, which features 80+ figures, please visit https://www.rootsanalysis.com/reports/dna-damage-response-targeting-therapeutics-market.html

The market is characterized by the presence of large companies (more than 500 employees), mid-sized players (51-500 employees), small companies (11-50 employees) and very small companies (2-10 employees). It is worth mentioning that small companies are pre-dominantly contributing to this field (XX%). Notably, the industry has also witnessed contributions from several large firms (XX%). such as (in alphabetical order) XX, AstraZeneca, XX, Bristol Myers Squibb, XX, XX and Vertex Pharmaceuticals.

In North America, the US (XX) emerged as the most prominent region wherein majority of the DDR targeting therapeutics developers are located, followed by Canada (XX). While most of the developers are based in UK (XX) in Europe, maximum number of players are headquartered in Australia and Japan (XX each) within the Asia-Pacific region. XX emerged as the leading developer in this domain, having the maximum (XX) number of DDR targeting therapeutics in its current pipeline. Most (XX) of the drug candidates of the aforementioned firm are currently in preclinical stages. This is followed by XX, XX, XX, XX, Senhwa Biosciences and XPose Therapeutics, having XX drug candidates, each.

Majority (XX%) of the clinical stage DDR targeting therapies are being evaluated in phase I trials, followed by those currently in phase II (XX%) and phase I / II (XX%) studies. Further, majority (XX%) of the preclinical drug candidates are in preclinical (unspecified) stages, followed by those in discovery (25%) and lead optimization (XX%) stages. Notably, majority of the clinical DDR targeting therapeutics are being developed to target ATR (XX%), followed by those designed for WEE1 (8%) molecules. DNA-PK, p53, RNA polymerase I and APE1/Ref-1 are other popular target molecules for clinical stage candidates.

To request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis.com/reports/dna-damage-response-targeting-therapeutics-market/free-insights.html

It is worth mentioning that majority (XX) of the clinical stage drug candidates target solid tumors, followed by those being developed for the treatment of leukemia (XX) and myelodysplastic syndrome (XX). Examples of therapies targeting myelodysplastic syndrome include (in reverse order of phase of development) XX (phase III), XX (phase II), and XX (phase II), XX (phase I), XX (phase I) and XX (phase I).

Further, majority (XX) of the preclinical stage DDR targeting therapies are being developed for cancer (unspecified), followed by those intended for the treatment of solid tumors (unspecified) (XX). In recent years, players from across the globe have initiated research to evaluate the therapeutic potential of DDR targeting drug candidates against non-oncological indications, including Alzheimer’s disease and Parkinson’s disease.

For more information, please click on the following link: - https://www.rootsanalysis.com/reports/dna-damage-response-targeting-therapeutics-market.html

Other Recent Offerings

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Details

Ben Johnson

+1 (415) 800 3415

[email protected]

Roots Analysis

Web: https://www.rootsanalysis.com/

LinkedIn: https://in.linkedin.com/company/roots-analysis

Twitter: https://twitter.com/RootsAnalysis.com

Medium: https://medium.com/@RootsAnalysis

Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/

Quora: https://rootsanalysisinsights.quora.com/